Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Current Assets (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Current Assets for 11 consecutive years, with $24.7 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Current Assets fell 22.29% year-over-year to $24.7 million, compared with a TTM value of $24.7 million through Jun 2025, down 22.29%, and an annual FY2024 reading of $29.7 million, up 526.97% over the prior year.
  • Current Assets was $24.7 million for Q2 2025 at Kiora Pharmaceuticals, down from $29.7 million in the prior quarter.
  • Across five years, Current Assets topped out at $33.5 million in Q1 2024 and bottomed at $4.4 million in Q2 2022.
  • Average Current Assets over 5 years is $14.2 million, with a median of $8.0 million recorded in 2021.
  • The sharpest move saw Current Assets plummeted 44.19% in 2022, then skyrocketed 526.97% in 2024.
  • Year by year, Current Assets stood at $9.0 million in 2021, then fell by 26.32% to $6.6 million in 2022, then decreased by 28.47% to $4.7 million in 2023, then surged by 526.97% to $29.7 million in 2024, then decreased by 16.73% to $24.7 million in 2025.
  • Business Quant data shows Current Assets for KPRX at $24.7 million in Q2 2025, $29.7 million in Q4 2024, and $31.7 million in Q3 2024.